Press Release

Press Release - Q2FY27 - Consolidated operating revenue Rs 4,389 Cr +2% y-y; EBITDA Rs 865 Cr -7% y-y; Net Profit Rs 41 Cr -52% y-y - Biopharma revenue up 5% y-y to Rs 3,583 Cr; Biosimilars +3%, Generics +10% - Services revenue down 9% y-y; Syngene revenue up 13% q-o-q with 6ppt margin improvement - Secured 10-year biosimilar Pertuzumab partnership in Brazil valued ~USD 400 million - EMA recommended biosimilar Pertuzumab under new clinical pathway; US and Europe launch visibility secured - Insulin Glargine fill-finish line operational in Malaysia; commercial supplies underway - Strong US demand for insulin and biosimilars Yesafili and Yesintek; 13 product launches in emerging markets - Interest cost down 12% y-y; R&D expenses stable; EBITDA margin at 20% - Management confident on growth trajectory and stronger H2FY27 performance